SRK-441

About Scholar Rock Holding

Scholar Rock is a clinical-stage biopharmaceutical company founded on a paradigm-shifting scientific strategy: targeting the latent, inactive forms of growth factors, particularly within the TGFβ superfamily, to achieve precise, localized therapeutic effects. The company's most advanced asset, apitegromab, has demonstrated promising Phase 3 results in spinal muscular atrophy (SMA) and is positioned as a potential first-in-class muscle-targeted therapy. Supported by a robust proprietary platform and a strong financial position, Scholar Rock's strategy extends beyond neuromuscular diseases into cardiometabolic disorders and immuno-oncology, aiming to build a diversified portfolio of novel biologics.

Therapeutic Areas

Other Fibrotic Diseases Drugs